|
1
|
National Comprehensive Cancer Network, .
NCCN clinical practice guidelines in oncology-colon cancer (version
2, 2019). https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
|
|
2
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Loupakis F, Yang D, Yau L, Feng S,
Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ,
et al: Primary tumor location as a prognostic factor in metastatic
colorectal cancer. J Natl Cancer Inst. 107:dju4272015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weiss JM, Pfau PR, O'Connor ES, King J,
LoConte N, Kennedy G and Smith MA: Mortality by stage for right-
versus left-sided colon cancer: Analysis of surveillance,
epidemiology, and end results-Medicare data. J Clin Oncol.
29:4401–4409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ishihara S, Murono K, Sasaki K, Yasuda K,
Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Hata K, et
al: Impact of primary tumor location on postoperative recurrence
and subsequent prognosis in nonmetastatic colon cancers: A
multicenter retrospective study using a propensity score analysis.
Ann Surg. 267:917–921. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holch JW, Ricard I, Stintzing S, Modest DP
and Heinemann V: The relevance of primary tumour location in
patients with metastatic colorectal cancer: A meta-analysis of
first-line clinical trials. Eur J Cancer. 70:87–98. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petrelli F, Tomasello G, Borgonovo K,
Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G and Barni S:
Prognostic survival associated with left-sided vs. right-sided
colon cancer: A systematic review and meta-analysis. JAMA Oncol.
3:211–219. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tejpar S, Stintzing S, Ciardiello F,
Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ and Heinemann
V: Prognostic and predictive relevance of primary tumor location in
patients with RAS wild-type metastatic colorectal cancer:
Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA
Oncol. 3:194–201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arnold D, Lueza B, Douillard JY, Peeters
M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP,
Tabernero J, et al: Prognostic and predictive value of primary
tumour side in patients with RAS wild-type metastatic colorectal
cancer treated with chemotherapy and EGFR directed antibodies in
six randomized trials. Ann Oncol. 28:1713–1729. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boeckx N, Koukakis R, Op de Beeck K, Rolfo
C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T and
Peeters M: Primary tumor sidedness has an impact on prognosis and
treatment outcome in metastatic colorectal cancer: Results from two
randomized first-line panitumumab studies. Ann Oncol. 28:1862–1868.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Breivik J, Lothe RA, Meling GI, Rognum TO,
Børresen-Dale AL and Gaudernack G: Different genetic pathways to
proximal and distal colorectal cancer influenced by sex-related
factors. Int J Cancer. 74:664–669. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iacopetta B: Are there two sides to
colorectal cancer? Int J Cancer. 101:403–408. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hutchins G, Southward K, Handley K, Magill
L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M,
Kerr D, et al: Value of mismatch repair, KRAS, and BRAF mutations
in predicting recurrence and benefits from chemotherapy in
colorectal cancer. J Clin Oncol. 29:1261–1270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen H, Yang J, Huang Q, Jiang MJ, Tan YN,
Fu JF, Zhu LZ, Fang XF and Yuan Y: Different treatment strategies
and molecular features between right-sided and left-sided colon
cancers. World J Gastroenterol. 21:6470–6478. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shimada Y, Kameyama H, Nagahashi M,
Ichikawa H, Muneoka Y, Yagi R, Tajima Y, Okamura T, Nakano M,
Sakata J, et al: Comprehensive genomic sequencing detects important
genetic differences between right-sided and left-sided colorectal
cancer. Oncotarget. 8:93567–93579. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yan HHN, Lai JCW, Ho SL, Leung WK, Law WL,
Lee JFY, Chan AKW, Tsui WY, Chan ASY, Lee BCH, et al: RNF43
germline and somatic mutation in serrated neoplasia pathway and its
association with BRAF mutation. Gut. 66:1645–1656. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eto T, Miyake K, Nosho K, Ohmuraya M,
Imamura Y, Arima K, Kanno S, Fu L, Kiyozumi Y, Izumi D, et al:
Impact of loss-of-function mutations at the RNF43 locus on
colorectal cancer development and progression. J Pathol.
245:445–455. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lai C, Sun W, Wang X, Xu X, Li M, Huang D,
Xu E, Lai M and Zhang H: RNF43 frameshift mutations contribute to
tumourigenesis in right-sided colon cancer. Pathol Res Pract.
215:1524532019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi
ST, Siu HC, Deng S, Chu KM, Law S, et al: Whole-genome sequencing
and comprehensive molecular profiling identify new driver mutations
in gastric cancer. Nat Genet. 46:573–582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang X, Hao HX, Growney JD, Woolfenden S,
Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, et al:
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic
ductal adenocarcinoma. Proc Natl Acad Sci USA. 110:12649–12654.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ryland GL, Hunter SM, Doyle MA, Rowley SM,
Christie M, Allan PE, Bowtell DD; Australian Ovarian Cancer Study
Group, ; Gorringe KL and Campbell IG: RNF43 is a tumour suppressor
gene mutated in mucinous tumours of the ovary. J Pathol.
229:469–476. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Giannakis M, Hodis E, Jasmine Mu X,
Yamauchi M, Rosenbluh J, Cibulskis K, Saksena G, Lawrence MS, Qian
ZR, Nishihara R, et al: RNF43 is frequently mutated in colorectal
and endometrial cancers. Nat Genet. 46:1264–1266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Serra S and Chetty R: Rnf43. J Clin
Pathol. 71:1–6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO classification of tumours of the digestive system.
4th. IARC; Lyon: 2010
|
|
25
|
Hashimoto T, Yamashita S, Yoshida H,
Taniguchi H, Ushijima T, Yamada T, Saito Y, Ochiai A, Sekine S and
Hiraoka N: WNT pathway gene mutations are associated with the
presence of dysplasia in colorectal sessile serrated
adenoma/polyps. Am J Surg Pathol. 41:1188–1197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsai JH, Liau JY, Yuan CT, Lin YL, Tseng
LH, Cheng ML and Jeng YM: RNF43 is an early and specific mutated
gene in the serrated pathway, with increased frequency in
traditional serrated adenoma and its associated malignancy. Am J
Surg Pathol. 40:1352–1359. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sekine S, Yamashita S, Tanabe T, Hashimoto
T, Yoshida H, Taniguchi H, Kojima M, Shinmura K, Saito Y, Hiraoka
N, et al: Frequent PTPRK-RSPO3 fusions and RNF43 mutations in
colorectal traditional serrated adenoma. J Pathol. 239:133–138.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th. Springer;
New York: 2010
|
|
29
|
Watanabe T, Muro K, Ajioka Y, Hashiguchi
Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S,
et al: Japanese society for cancer of the colon and rectum (JSCCR)
guidelines 2016 for the treatment of colorectal cancer. Int J Clin
Oncol. 23:1–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nagahashi M, Wakai T, Shimada Y, Ichikawa
H, Kameyama H, Kobayashi T, Sakata J, Yagi R, Sato N, Kitagawa Y,
et al: Genomic landscape of colorectal cancer in Japan: Clinical
implications of comprehensive genomic sequencing for precision
medicine. Genome Med. 8:1362016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shimada Y, Yagi R, Kameyama H, Nagahashi
M, Ichikawa H, Tajima Y, Okamura T, Nakano M, Nakano M, Sato Y, et
al: Utility of comprehensive genomic sequencing for detecting
HER2-positive colorectal cancer. Hum Pathol. 66:1–9. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shimada Y, Tajima Y, Nagahashi M, Ichikawa
H, Oyanagi H, Okuda S, Takabe K and Wakai T: Clinical significance
of BRAF Non-V600E mutations in colorectal cancer: A retrospective
study of two institutions. J Surg Res. 232:72–81. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Oyanagi H, Shimada Y, Nagahashi M,
Ichikawa H, Tajima Y, Abe K, Nakano M, Kameyama H, Takii Y,
Kawasaki T, et al: SMAD4 alteration associates with invasive-front
pathological markers and poor prognosis in colorectal cancer.
Histopathology. 74:873–882. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Boland CR, Thibodeau SN, Hamilton SR,
Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA,
Fodde R, Ranzani GN and Srivastava S: A national cancer institute
workshop on microsatellite instability for cancer detection and
familial predisposition: Development of international criteria for
the determination of microsatellite instability in colorectal
cancer. Cancer Res. 58:5248–5257. 1998.PubMed/NCBI
|
|
36
|
Cancer Genome Atlas Network, .
Comprehensive molecular characterization of human colon and rectal
cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Colorectal Adenocarcinoma. TCGA, PanCancer
data. https://www.cell.com/pb-assets/consortium/pancanceratlas/pancani3/index.html
|
|
38
|
Tol J, Nagtegaal ID and Punt CJ: BRAF
mutation in metastatic colorectal cancer. N Engl J Med. 361:98–99.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Peeters M, Oliner KS, Parker A, Siena S,
Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, André T, Wiezorek
J, et al: Massively parallel tumor multigene sequencing to evaluate
response to panitumumab in a randomized phase III study of
metastatic colorectal cancer. Clin Cancer Res. 19:1902–1912. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Seymour MT, Brown SR, Middleton G, Maughan
T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N,
et al: Panitumumab and irinotecan versus irinotecan alone for
patients with KRAS wild-type, fluorouracil-resistant advanced
colorectal cancer (PICCOLO): A prospectively stratified randomised
trial. Lancet Oncol. 14:749–759. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee DW, Han SW, Kang JK, Bae JM, Kim HP,
Won JK, Jeong SY, Park KJ, Kang GH and Kim TY: Association between
fusobacterium nucleatum, pathway mutation, and patient
prognosis in colorectal cancer. Ann Surg Oncol. 25:3389–3395. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hamada T, Zhang X, Mima K, Bullman S,
Sukawa Y, Nowak JA, Kosumi K, Masugi Y, Twombly TS, Cao Y, et al:
Fusobacterium nucleatum in colorectal cancer relates to
immune response differentially by tumor microsatellite instability
status. Cancer Immunol Res. 6:1327–1336. 2018. View Article : Google Scholar : PubMed/NCBI
|
